Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletions.

Pediatric blood & cancer - 1 Apr 2021

Huang Ying-Jung, Liu Hsi-Che, Jaing Tang-Her, Wu Kang-Hsi, Wang Shih-Chung, Yen Hsiu-Ju, Hsiao Chih-Cheng, Chen Shih-Hsiang, Lin Pei-Chin, Yeh Ting-Chi, Sheen Jiunn-Ming, Chen Yu-Chieh, Chang Te-Kau, Huang Fang-Liang, Chao Yu-Hua, Hou Jen-Yin, Yang Chao-Ping, Lin Tung-Huei, Shih Lee-Yung

Abstract excerpt

BACKGROUND: IKZF1deletion is an unfavorable factor in Philadelphia negative (Ph -) B-cell acute lymphoblastic leukemia. However, the effects of IKZF1 deletions co-existing genetic alterations in Ph (-) ALL have not been extensively studied. METHODS: Bone marrow samples from 368 children with Ph (-) ALL were analyzed by using multiplex ligation-dependent probe amplification kit for detection of gene deletions and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child, Preschool
Share to Gene Deletion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ikaros Transcription Factor

Share to Infant

Share to Philadelphia Chromosome

Share to Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Share to ras Proteins

Share to Signal Transduction

Source

Identifiers

PMID: 33522704
DOI: 10.1002/pbc.28899

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletions.PMID 33522704Read ↗

IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemiaSemantic proximity Read ↗

IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly.Semantic proximity Read ↗

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemiaSemantic proximity Read ↗

High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.Semantic proximity Read ↗

Multi-Lineage BCR-ABL Expression in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Associated With Improved Prognosis but No Specific Molecular FeaturesSemantic proximity Read ↗

[Research Progress on Pathogenic Genes of Ph-like Acute Lymphoblastic Leukemia--Review].Semantic proximity Read ↗

Simultaneous detection of ABL1 mutation and IKZF1 deletion in Philadelphia chromosome-positive acute lymphoblastic leukemia using a customized target enrichment system panel.Semantic proximity Read ↗

Quantitative analysis of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia: Higher levels are associated with a poorer prognosisSemantic proximity Read ↗

Prognostic Value of Rare IKZF1 deletions in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia: An International Collaborative StudySemantic proximity Read ↗

Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

The Clinical Relevance of RAS Pathway Gene Mutations in Pediatric B-Cell Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.